Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study by Andres D Ruiz et al.
RESEARCH ARTICLE Open Access
Effectiveness of Compounded Bioidentical
Hormone Replacement Therapy: An Observational
Cohort Study
Andres D Ruiz2,3, Kelly R Daniels1,2,3, Jamie C Barner1, John J Carson3 and Christopher R Frei1,2*
Abstract
Background: Bioidentical Hormone Replacement Therapy (BHRT) is believed it to be a safer and equally effective
alternative to Conventional Hormone Therapy for the relief of menopausal symptoms; however, data are needed to
support these claims. The objective of this study is to evaluate the effectiveness of compounded BHRT provided in
six community pharmacies.
Methods: This was an observational cohort study of women between the ages of 18-89 who received a
compounded BHRT product from January 1, 2003 to April 30, 2010 in six community pharmacies. Data included
patient demographics, comorbidities, therapeutic outcomes, and hormone therapies. Women self-rated
menopausal symptoms as absent, mild, moderate, or severe. Descriptive statistics were used to characterize the
patient population, BHRT use, and adverse events. Patient symptom severity was compared at baseline and 3 to 6
months follow-up using the Wilcoxon signed-rank test.
Results: Women (n = 296) receiving BHRT at Oakdell Pharmacy had a mean (standard deviation) age of 52 (9)
years. The most common BHRT dosage forms utilized were topical (71%) and oral (43%). Compounded BHRT
regimens were generally initiated at low doses regardless of route. Women experienced a 25% decrease in
emotional lability (p < 0.01), a 25% decrease in irritability (p < 0.01), and a 22% reduction in anxiety (p = 0.01)
within 3 to 6 months. These women also experienced a 14% reduction in night sweats (p = 0.09) and a 6%
reduction in hot flashes (p = 0.50).
Conclusions: This study demonstrates that compounded BHRT improves mood symptoms. Larger studies are
needed to examine the impact on vasomotor symptoms, myocardial infarction and breast cancer.
Background
Bioidentical Hormone Replacement Therapy (BHRT)
describes supplementation of hormones that are mole-
cularly identical to those hormones produced in the
human body. Unlike manufactured Conventional Hor-
mone Therapy (CHT), such as conjugated estrogens
(CE) and medroxyprogesterone acetate (MPA), BHRT
hormones do not contain extra structural moieties
which may alter hormone receptor binding and function
in the human body.
The Professional Compounding Centers of America
(PCCA) estimates that 1 in 4 compounded products in
the United States are a form of Hormone Replacement
Therapy (HRT) [1]. Compounded BHRT is a form of
personalized medicine whereby the dose, regimen, and
dosage forms are customized based on the patient’s
symptoms, hormone levels, and preferences. Hormone
levels are obtained by either serum or salivary testing
and are measured to assess a woman’s hormonal stage
of life and to create customized therapies. The idea is
that these individualized preparations containing bioi-
dentical hormones may improve the safety and effective-
ness of treating menopausal symptoms. Compounded
BHRT is perceived to be more effective, better tolerated,
with fewer health risks than its CHT counterpart [2-4].
This study first describes the characteristics and
prescribing patterns of compounded BHRT in six
community pharmacies. Three specific aims are then
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addressed: (1) determine if compounded BHRT is effec-
tive in treating menopausal symptoms, (2) identify
which BHRT compounds are most effective, and (3)
determine if compounded BHRT is safe.
Methods
This was an observational cohort study of female
patients age 18-89 treated for menopause-related hor-
mone imbalances from January 1, 2003 to April 30,
2010 in six community pharmacies. The University of
Texas Health Science Center at San Antonio Institu-
tional Review Board reviewed and approved this study;
protocol number HSC20090507H. Oakdell Pharmacy,
Inc. is comprised of six independent community phar-
macies located throughout San Antonio, Texas and has
offered BHRT consultation services since 2003. Cur-
rently, more than 1,000 women receive their com-
pounded BHRT at Oakdell Pharmacy. Patient charts are
maintained locally at the pharmacy.
Pharmacists who provide BHRT consultation services
at Oakdell Pharmacy are trained through PCCA educa-
tional symposiums and other BHRT-focused seminars.
At these seminars, credentialed medical professionals (e.
g., physicians and pharmacists) provide evidence-based
BHRT education. In addition, pharmacists who care for
BHRT patients at Oakdell must have BHRT-related con-
tinuing education credit.
Patients are referred to the Oakdell Wellness Center
through physicians, family members, and friends. BHRT
consultation services consist of an extensive initial eva-
luation, hormone replacement education, and follow-up
visits. Patients complete a new patient evaluation form
and a laboratory hormone panel prior to their initial
visit. This hormone panel, determined through serum or
salivary testing, aids in identification of sex hormone
deficiencies, adrenal function deficiencies, and thyroid
dysfunction. Additional hormone panels are recom-
mended 3-6 months after BHRT initiation, annually,
and when deemed necessary to assist with BHRT custo-
mization. During the initial evaluation, patients are
questioned regarding medical history, menopausal symp-
toms, and treatment goals. They are educated on several
components of hormone therapy including: hormonal
changes of menopause, causative factors associated with
menopausal symptoms, risks and benefits of hormone
therapy (both conventional and bioidentical therapies),
and different BHRT dosage forms. During initial evalua-
tion and follow-up visits, pharmacists use a standardized
form to monitor symptom resolution and adverse
effects. This form lists several symptoms associated with
menopause. Patients are asked to indicate whether their
symptoms are “absent,” “mild,” “moderate,” or “severe.”
The pharmacist and patient decide on an indivi-
dualized treatment plan consisting of either (1) a
prescription recommendation to be faxed to their physi-
cian for modification, signature, and approval and/or (2)
over-the-counter (OTC) products. The pharmacist’s let-
ter to the physician describes the patient’s hormone
imbalance(s), laboratory results, and current menopausal
symptoms. It also suggests a customized BHRT regimen
and outlines the benefits of compounded BHRT. BHRT
compounds vary by active ingredients, dose, and dosage
form. Once the physician’s approval is received, the
individualized BHRT compound is prepared. The most
common compounded BHRT hormones include: biest
(estriol/estradiol in varying concentrations), triest
(estriol/estradiol/estrone), progesterone, testosterone,
and dehydroepiandosterone (DHEA). Table 1 depicts
common bioidentical hormone dose classifications.
Patients are instructed to complete monthly evaluation
forms for the first few months and every six months
thereafter to monitor menopausal symptoms and side
effects. Upon review of a patient’s evaluation form, the
pharmacist decides if further laboratory work, telephone,
or face-to-face follow-up is needed. The pharmacist
then makes changes to the patient’s therapy in consulta-
tion with the patient and their physician.
Patient Eligibility
Women ≥18 years of age receiving compounded BHRT
at Oakdell Pharmacy Inc., from January 1, 2003 to April
30, 2010 were eligible for this study. Patients were
excluded if they received compounded BHRT from Oak-
dell Pharmacy, but were managed outside the Oakdell
Pharmacy system (i.e., physicians’ offices). Patients were
Table 1 Common Compounded Bioidentical Hormones
Dose Classifications
Dose Classification Dose Range
Topical Estrogen
Low Dose ≤0.5 mg
Moderate Dose 0.51-1 mg
High Dose >1 mg
Oral Estrogen
Low Dose ≤1 mg
Moderate Dose 1.1-2 mg
High Dose >2 mg
Topical Progesterone
Low Dose <20 mg
Moderate Dose 21-50 mg
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also excluded if they did not complete a follow-up
hormone evaluation form. All data were collected at
Oakdell Pharmacy from the existing medical records.
Data Collection
A customized, data collection instrument was developed
using Microsoft Access 2007® software. The instrument
was designed to mimic the appearance of the initial
patient intake and follow-up forms used during pharma-
cist consultations at Oakdell Pharmacy. All research per-
sonnel were trained on the tool prior to collection of
any patient data. Data included patient demographics,
comorbidities, laboratory values, medications, and
adverse effects of hormone therapy. The last-observa-
tion-carried-forward (LOCF) method was used to deter-
mine BHRT effectiveness at 3 and 6 months follow-up.
If patient data were available at 6 months, those data
were used. That is, if patient data were available at 3
months, but not 6 months, then the data from 3 months
were used. LOCF is an accepted method used by other
HRT studies [5-7].
The dependent variables utilized in this study were
vasomotor symptoms, mood symptoms, myocardial
infarction, and breast cancer. A decrease in symptom
intensity was defined as a decrease in symptom ratings
from baseline to follow-up (three to six months). Base-
line and follow-up symptom ratings were also com-
pared at each time point using the percentage of
patients reporting either “moderate” or “severe.”
Reduction in symptom severity was also evaluated in a
subgroup analysis of women between the ages of 40
and 70 years.
Myocardial infarction and breast cancer adverse event
rates were reported as events and cases per 10,000 per-
son years. Adverse event (AE) rates were calculated with
the following method: number of AE/[(average time to
AE) X (# of patients with AE follow-ups). This number
was then multiplied by 10,000 to give AE rates per
10,000 person years.
The independent variables utilized in this study were
BHRT regimen and BHRT dosage form. The term
“estrogen” was used to describe the use of any of the
estrogen combinations [i.e., triest (estriol 80%/estradiol
10%/estrone 10%), biest (estriol 80%/estradiol 20%),
biest (estriol 70%/estradiol 30%), and biest (estriol 50%/
estradiol 50%)].
Patient’s length of therapy (LOT) was obtained from
the pharmacy records and patient charts. LOT was cal-
culated using the following method: date of most cur-
rent BHRT prescription fill minus date of original fill.
The patient’s treatment timeframe was obtained from
pharmacy records and was calculated as the date of fol-
low-up minus the date of baseline assessment.
Data and Statistical Analysis
All statistical analyses were performed using JMP 8.0®
(SAS Corp., Cary, NC). Statistical significance was
defined as an alpha less than 0.05. Descriptive statistics
(e.g., means, medians, and frequencies) were used to
characterize the patient demographics, BHRT use,
symptom resolution, and adverse effects. Patient demo-
graphics, baseline characteristics, comorbid conditions,
baseline menopausal symptoms, dosing regimens, symp-
tom improvement, and adverse effects were compared
between groups. Categorical variables were compared
using chi-square and Fisher’s exact tests. Continuous
variables were tested for normality using the Shapiro
Wilk-W Test. Normally distributed variables were
reported as means (standard deviations), while non-nor-
mally distributed variables were reported as medians
(25th and 75th percentiles). Paired data were compared




Of 431 charts reviewed, 296 women met study criteria.
The mean (standard deviation) age was 52 (9) years and
the mean weight was 153 (32) lbs. Only 1% of women
reported a history of heart disease; however, nearly one-
quarter of women reported at least one of the following
CHD risk factors: dyslipidemia (21%), hypertension
(12%), or diabetes (4%). Few women reported a history
of thyroid disorders (14%), cancer (3%), or coagulopa-
thies (2%). One-third of the women had a hysterectomy
and one-quarter had an oophorectomy. Many women
reported caffeine (73%) or alcohol (54%) use, but few
reported tobacco (8%) use. The majority of women had
not received prior hormone therapy; 8% reported prior
CHT use and 13% reported prior BHRT use. When
compared to those women who were excluded, women
included in this study were more likely to have had a
hysterectomy (p = 0.02), previous BHRT use (p < 0.01),
and previous CHT use (p < 0.01) at baseline.
BHRT use Characteristics at Oakdell Pharmacy
All women received progesterone (P4) as monotherapy
(43%) or in combination with estrogen (57%). Few base-
line characteristics differed between women on P4
monotherapy and estrogen + P4 combination therapy
(Table 2). Women initiated on P4 monotherapy were
younger (50 vs. 53 years, p < 0.01), less likely to be hys-
terectomized (27% vs. 38%, p = 0.02) and oophorecto-
mized (21% vs. 32%, p = 0.04), and more likely to have
a history of hypertension (17% vs. 9%, p = 0.04).
Various compounded BHRT dosage forms were uti-
lized (Figure 1). Topical therapy was used most often
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(72%), followed by oral (43%), vaginal (23%), and sublin-
gual (4%) therapy. Some women received multiple
dosage forms simultaneously. Women receiving a single
dosage form were initiated on topical therapy most
often (40%), followed by oral (20%) and sublingual (2%).
Women receiving combination dosage forms were
initiated on topical+oral therapy most often (16%), fol-
lowed by topical+vaginal therapy (12%), topical+oral
+vaginal therapy (4%), oral+vaginal therapy (4%), and
sublingual+oral therapy (2%). Women initiated on P4
monotherapy received more topical therapy (83% vs.
63%), and less oral (27% vs. 55%), vaginal (14% vs. 28%),
and sublingual therapies (2% vs. 6%) than women
initiated on estrogen + P4 combination therapy.
Therapy was generally initiated at low doses (Figure 2
and Figure 3). Low-dose progesterone monotherapy was
initiated in 65% of patients receiving topical therapy and
78% of patients receiving oral therapy. Low-dose estro-
gen was initiated in 63% of patients receiving topical
therapy and 48% of patients receiving oral therapy. Biest
50/50 (51%) and biest 80/20 (45%) were the most com-
mon topical estrogen combination therapies. Biest 50/50
(53%) and triest (35%) were the most common oral
estrogen combination therapies. These estrogen combi-
nation therapies were also frequently initiated at low
doses.
BHRT Effectiveness
Women initiated on compounded BHRT experienced
significant reductions in moderate to severe mood
symptoms within 3 to 6 months (Figure 4). Overall,
women experienced a 25% decrease in emotional lability
(53% vs. 28%, p < 0.01), a 25% decrease in irritability
(58% vs. 33%, p < 0.01), and a 22% reduction in anxiety
(49% vs. 27%, p = 0.01).
Women receiving compounded BHRT also experienced
non-significant reductions in vasomotor symptoms within
3 to 6 months of therapy. Night sweats were reduced by
14% (46% vs. 32%, p = 0.09) and hot flashes were reduced
by 6% (48% vs. 42%, p = 0.5) (Figure 4).
Women initiated on P4 monotherapy generally experi-
enced a greater reduction in moderate to severe mood
symptoms within 3 to 6 months compared to women
initiated on estrogen + P4 combination therapy (Figure
5 and Figure 6). Women receiving P4 monotherapy
experienced a 28% reduction in emotional lability (56%
vs. 28%, p = 0.04), a 30% decrease in irritability (65% vs.
35%, p = 0.04), and a 31% reduction in anxiety (58% vs.
27%, p = 0.04). Although non-significant, women
initiated on estrogen + P4 combination therapy experi-
enced a 22% reduction in emotional lability (50% vs.
28%, p = 0.07), a 20% decrease in irritability (52% vs.








(Estrogen + P4 vs.
P4)
Age (yrs); mean (SD) 53 (7) 50 (10) <0.01
Weight (lbs); mean
(SD)
152 (32) 155 (32) 0.49
Comorbid Conditions; %
Heart disease 2 1 0.46
Dyslipidemia 22 20 0.60
Hypertension 9 17 0.04
Diabetes 5 2 0.28
Cancer 2 3 0.67
Thyroid 14 13 0.72
Coagulopathies 2 1 0.28
Hysterectomized; % 38 27 0.02
Ovaries Removed; % 32 21 0.04
Tobacco use; % 8 9 0.95
Caffeine use; % 70 79 0.18
Alcohol use; % 54 52 0.51
Baseline CHT; % 8 9 0.74
Baseline BHRT; % 15 10 0.17
Figure 1 Baseline BHRT Dosage Forms at Oakdell Pharmacy, n = 296.
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32%, p = 0.15), and a 13% reduction in anxiety (41% vs.
28%, p = 0.29). Moderate to severe night sweats
decreased by 15% in women who received P4 monother-
apy (46% vs. 31%, p = 0.34) and 14% in women who
received estrogen + P4 combination therapy (47% vs.
33%, p = 0.39). Hot flashes were reduced by 15% with
P4 monotherapy (54% vs. 39%, p = 0.39) and no
improvements were seen with estrogen + P4 combina-
tion therapy (44% vs. 44%, p = 1.0).
We also performed a subgroup analysis to determine
the effectiveness of compounded BHRT in women
between the ages of 40 and 70 years (Figure 7). This age
group more closely represents those women who are
more likely to be affected by menopausal symptoms. The
results seen were similar to those in the primary analysis.
There was a 3% decrease in hot flashes (53% vs. 50%, p =
0.79) and a 15% decrease in night sweats (48% vs. 33%, p
= 0.2). These women also experienced a 37% reduction
in irritability (53% vs. 16%, p < 0.001), a 33% reduction in
anxiety (53% vs. 20%, p < 0.01), and a 31% decrease in
emotional lability (50% vs. 19%, p < 0.01).
BHRT Safety
From this cohort of 296 women initiated on com-
pounded BHRT, 62 (21%) had documented follow-up
regarding myocardial infarction and breast cancer.
These 62 women had an average follow-up of 1.9 years
for a total of 117 person years. During this timeframe,
no woman initiated on compounded BHRT experienced
a myocardial infarction (MI) or breast cancer.
Figure 2 Topical BHRT Doses at Baseline, n = 210.
Figure 3 Oral BHRT Doses at Baseline, N = 128.
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Discussion
This study confirms that compounded BHRT is effective
for improving mood symptoms. We were unable to
draw firm conclusions regarding the utility of com-
pounded BHRT for vasomotor symptoms, but the
observed trends are encouraging. Similar trends were
seen in the subgroup analysis of women between the
ages of 40 and 70 years.
This is the first time “compounded” BHRT therapy
has been evaluated, but there are several studies that
confirm the effectiveness of “manufactured” BHRT.
Trials have shown estrone (E1) and estradiol (E2) to be
effective for reducing menopausal symptoms as mono-
therapy or combination therapy, but trials have not been
conducted to evaluate the effectiveness of estriol (E3).
The effectiveness of E1 for reducing the severity of
menopausal symptoms has been observed. Takahashi [7]
conducted an open label trial in 53 women receiving 2
mg E1 for 12 months. Menopausal relief was evaluated
using the Kupperman index (KI) for severity. Women
who underwent natural menopause experienced a 50%
Figure 4 Effectiveness of Compounded BHRT to Alleviate Moderate to Severe Menopausal Symptoms.
Figure 5 Effectiveness of P4 Monotherapy to Alleviate Moderate to Severe Menopausal Symptoms.
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reduction in their KI score (p < 0.01), whereas women
who underwent surgical menopause experienced an 80%
reduction in their score (p < 0.01). The KI is a numeri-
cal conversion index of 11 menopausal symptoms
(including vasomotor and mood symptoms) designed to
measure total menopausal relief. Although individual
symptoms were not evaluated, E1 was shown to be
effective for relief of composite menopausal symptoms.
Large randomized controlled trials (RCTs) have docu-
mented E2’s effectiveness for relieving menopausal
symptoms [8,9]. Simon and colleagues [8] conducted a
RCT in 484 women randomized to receive 0.87 grams/
day (0.52 mg E2), 1.7 grams/day (1.02 mg E2), or 2.6
grams/day of E2 gel (1.56 mg E2) for 12 weeks. Within
3 to 5 weeks, these women experienced a reduction in
hot flash severity (p < 0.01) and a reduction in hot flash
rate by at least 7 hot flashes/day (p < 0.001). Addition-
ally, the 1.7 grams/day E2 (1.02 mg E2) improved
patient’s Utian Quality of Life emotional score (0.9 vs.
0.2, p < 0.05). Similar to our method of evaluating
Figure 6 Effectiveness of Estrogen + P4 Therapy to Alleviate Moderate to Severe Menopausal Symptoms.
Figure 7 Effectiveness of Compounded BHRT in Women Ages 40 - 70 years.
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severity, women reported hot flashes as severity ratings,
yet limited numerical data were available to evaluate the
extent of vasomotor symptom reduction. We acknowl-
edge that the dose of E2 in our study was lower than
most commercially available products. This may be one
reason our study did not find a significant reduction in
vasomotor symptoms with these compounded BHRT
products.
Additionally, E1 and E3 combination therapy has been
shown to be effective for reducing menopausal symp-
toms. Padwick and colleagues [10] conducted a 6 month
RCT of 20 women randomized to receive oral E2 (2 mg)
or oral E1 (1 mg) + E2 (2 mg). This study evaluated
menopausal symptom relief using graphic rating scales.
Women randomized to receive oral E2 (2 mg) experi-
enced a significant reduction in hot flashes (62%, p <
0.01) and night sweats (77%, p < 0.01), and non-signifi-
cant improvements in anxiety (26%), irritability (18%),
and emotional lability (5%) (p values not given). Women
receiving oral E1 (1 mg) + E2 (2 mg) experienced signif-
icant reductions in hot flashes (41%, p < 0.01), night
sweats (56%, p < 0.05), and anxiety (44%, p < 0.01), and
non-significant improvements in irritability (32%) and
emotional lability (5%). Despite use of a different
method to evaluate symptom relief, this study provides
additional data that supports the use of combination
estrogens for reducing vasomotor and mood symptoms.
Although estrogens are generally regarded as the ther-
apeutic hormones in hormone replacement therapy [11],
P4 monotherapy has also been shown to be effective in
treating menopausal symptoms [12-14]. Leonetti and
colleagues [12] conducted a single-center RCT of 102
women within 5 years of menopause who were rando-
mized to receive P4 monotherapy (20 mg) or placebo.
Significant improvements or resolution of vasomotor
symptoms were seen at 4 months in P4-treated patients
compared to placebo (83% vs 19%; p < 0.001). Two
other RCTs have documented non-significant improve-
ments in menopausal symptoms [13,14]. Wren and col-
leagues [13] evaluated 80 women randomized to receive
topical P4 monotherapy (32 mg) or placebo. A reduction
in vasomotor (-1.0 vs. 0; p = 0.07) and anxiety (-1.0 vs.
0; p = 0.10) symptoms was reported at 12 weeks.
Another RCT conducted by Benster and colleagues [14]
randomized 223 women to receive P4 monotherapy (5
mg, 20 mg, 40 mg, and 60 mg) or placebo. The investi-
gators observed a reduction in vasomotor symptoms for
P4 5 mg (-0.4; p = 0.22), 20 mg (-0.4; p = 0.23), 40 mg
(-0.6; p = 0.06), and 60 mg (-0.4; p = 0.23). These trials
utilized the Greene Climacteric Scale, in which patients
self-rated their symptom severity (i.e. absent, mild, mod-
erate, and severe). This approach is similar to our study.
Manufactured E2 + P4 combination therapy has also
demonstrated effectiveness in reducing menopausal
symptoms. Vashisht and colleagues [15] conducted an
open label 48-week study in 41 women with the second-
ary objective of determining improvements in menopau-
sal symptoms. Treatment with E2 gel (1 mg) + P4
cream (40 mg) applied daily significantly reduced mod-
erate to severe vasomotor and anxiety symptoms at 24
weeks (p < 0.05). Anxiety was further reduced at 48
weeks of therapy when compared to the reduction at 24
weeks of therapy (p < 0.05). Similar to P4 monotherapy
trials, the Greene Climacteric Scale was utilized to eval-
uate mood and vasomotor symptom improvement.
Collectively, these findings support the effectiveness of
BHRT in reducing menopausal symptoms. Furthermore,
this study provides some of the first clinical evidence in
support of “compounded” BHRT.
BHRT Safety
Large RCTs by the Women’s Health Initiative (WHI)
and Heart and Estrogen/Progestin Replacement Study
(HERS) have documented deleterious effects associated
with CHT in postmenopausal women. Woman rando-
mized to receive CE + MPA combination therapy
experienced a 1.47 and 1.32 fold increase in non-fatal
MI in the HERS and WHI studies, respectively [16,17].
The WHI also demonstrated a 1.26 fold increase in
breast cancer in patients receiving CE + MPA [16].
There are currently no trials that evaluate BHRT risk
for MI and breast cancer. This study only had 117 per-
son-years of follow-up and none of these women experi-
enced an MI or breast cancer; however, the study lacks
a sufficient sample size to make firm statements about
the safety of compounded BHRT.
It is noteworthy that the Postmenopausal Estrogen/
Progestin Interventions (PEPI) trial, Gerhard trial, and
Estrogen in Prevention of Atherosclerosis (EPAT) trials
have all three demonstrated that BHRT improves cardi-
ovascular surrogate markers. Women in the PEPI trial
who received CE + cyclic P4 experienced a decreased in
LDL, increase in HDL, decrease in fibrinogen levels, and
decrease in fasting glucose compared to those women
on placebo [18]. Gerhard and colleagues [19] demon-
strated that women who received transdermal E2 +
cyclical vaginal P4 experienced improved vascular reac-
tivity and an 8.4% reduction in LDL compared to pla-
cebo. Finally, the EPAT trial demonstrated that women
who received oral E2 compared to placebo experienced
a decrease in carotid intima thickness progression,
increase in HDL, decrease in LDL, and decrease in
HbA1c [20]. Based on the favorable effects on cardiovas-
cular surrogate markers, BHRT may eventually prove to
be cardio-neutral or even cardioprotective.
Smaller RCTs provide encouraging results regarding
the impact of BHRT on breast cancer. Two RCTs by
Chang and colleagues [21] and Foidart and colleagues
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[22] demonstrated that women receiving topical P4
experienced a reduction in breast epithelial proliferative
markers via reductions in mitotic divisions and prolifer-
ating cell nuclear antigen (PCNA) labeling index % com-
pared to placebo. These studies support the belief that
P4 may prevent breast epithelial hyperplasia. A large
observational study demonstrated that women who used
E3 or estrogen + P4 combination therapy were not at
increased risk of breast cancer as compared to women
who had never used HRT [23].
Limitations
This study has strengths and limitations. First, these six
pharmacies were located in one geographical region;
therefore, these findings may not be generalized to all
settings. We detected a significant improvement in mood
symptoms; however, the sample size was insufficient to
assess the safety of compounded BHRT or its impact on
vasomotor symptoms. Our method of obtaining effective-
ness data also lends itself to potential rater bias. Patients
might have attempted to please the health care provider
by reporting improvement in menopausal symptoms.
Additionally, the rating scale utilized in the majority of
“manufactured” BHRT clinical trials differed from this
study. The Greene Climacteric Scale and The Kupperman
index may be more effective for evaluating menopausal
symptom outcomes with HRT. Also, this study did not
evaluate changes in regimens from baseline to follow-up
(3 to 6 months); therefore, improvements in menopausal
symptoms were attributed to the initial regimen women
received. Finally, the results of this study may be more
generalizable to hysterectomized women and those with
previous or current BHRT or CHT use since more
women were included in this study with those character-
istics compared to those women excluded.
Conclusions
Our study is one of the first to provide clinical evidence
for the effectiveness of compounded BHRT. Given the
deleterious effects of CHT observed in the WHI and
HERS trials, these data are of great value. Our study
provides clear evidence that compounded BHRT is
effective for reducing menopausal mood symptoms. Lar-
ger studies are needed to examine the impact of com-
pounded BHRT on vasomotor symptoms, myocardial
infarction, and breast cancer.
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